Australia Targets Patient Safety In Cell And Tissue Regulation Overhaul
Proposed changes to the Australian rules on the therapeutic use of autologous cells and tissues, intended to address growing concerns over how they are processed and administered to patients, could result in changes to how such products are classified as well as to the general regulatory framework for cell and tissue products.
You may also be interested in...
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
A “powerful new vision” for the post-Brexit UK regulatory framework was unveiled at a conference organized by the BioIndustry Association and the medicines regulator, the MHRA.
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.